非诺贝特(fenofibrate)为第三代苯氧乙酸类降脂药,1975年首次应用于临床,是目前临床上最常见的降脂药。非诺贝特参与体内脂肪酸的代谢、糖原、氨基酸及酮体的生成,近年来其抗肿瘤作用受到学者们的关注,成为新近的研究热点。 Fenofibrate, the third generation of phenoxyacetic lipid-lowering drugs, was first applied to clinic in 1975 and is the most common lipid-lowering drug in clinic at present. Fenofibrate is involved in the metabolism of fatty acids, the formation of glycogen, amino acids and ketone bodies in vivo. In recent years, its anti-tumor effect has attracted the attention of scholars and has become a new research hotspot.